RT Journal Article SR Electronic T1 Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.111549 DO 10.3899/jrheum.111549 A1 Nordström, Dan A1 Knight, Ann A1 Luukkainen, Reijo A1 van Vollenhoven, Ronald A1 Rantalaiho, Vappu A1 Kajalainen, Anna A1 Brun, Johan G. A1 Proven, Anne A1 Ljung, Lotta A1 Kautiainen, Hannu A1 Pettersson, Tom YR 2012 UL http://www.jrheum.org/content/early/2012/07/26/jrheum.111549.abstract AB Objective To study the efficacy of anakinra versus disease-modifying antirheumatic drugs (DMARD) in refractory adult-onset Still’s disease (AOSD). Methods In a 24-week study, 22 patients with AOSD taking prednisolone ≥ 10 mg/day received anakinra (n = 12) or DMARD (n = 10). The primary endpoint was achievement of remission. Results At 8 and 24 weeks, 7/12 and 6/12 receiving anakinra and 5/10 and 2/10 receiving DMARD achieved remission. Anakinra induced greater improvement in physical health measured by Medical Outcomes Study Short-Form 36 (SF-36; p < 0.011). During an open-label extension (OLE) of 28 weeks, 7/14 patients taking anakinra and 2/3 taking DMARD were in remission. Conclusion Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the OLE phase. (ClinicalTrials.gov Protocol Registration NCT01033656).